Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment

Background: Trastuzumab deruxtecan (T-DXd) shows efficacy in HER2-positive and HER2-low metastatic breast cancer (MBC), but its safety in patients with hepatic impairment is unclear. Methods: We report three cases of MBC patients with significant liver dysfunction treated with dose-reduced T-DXd aft...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Sun, Gaybrielle Moore, Annalise Labatut, Jane Meisel, Kevin Kalinsky, Kristina Byers
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621924000590
Tags: Add Tag
No Tags, Be the first to tag this record!